Chemoinformaics analysis of 2,4-Dodecadienamide, N-(2-methylpropyl)-, (2E,4E)-
| Molecular Weight | 251.414 | nRot | 10 |
| Heavy Atom Molecular Weight | 222.182 | nRig | 15 |
| Exact Molecular Weight | 251.225 | nRing | 0 |
| Solubility: LogS | -3.877 | nHRing | 0 |
| Solubility: LogP | 4.257 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 47 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 18 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 29 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 16 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 47.959 |
| nHD | 1 | BPOL | 30.531 |
| QED | 0.773 |
| Synth | 3.796 |
| Natural Product Likeliness | 1.966 |
| NR-PPAR-gamma | 0.9 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.004 |
| HIA | 0.022 |
| CACO-2 | -4.802 |
| MDCK | 0.0000154 |
| BBB | 0.071 |
| PPB | 0.992175 |
| VDSS | 1.329 |
| FU | 0.0290528 |
| CYP1A2-inh | 0.764 |
| CYP1A2-sub | 0.892 |
| CYP2c19-inh | 0.305 |
| CYP2c19-sub | 0.206 |
| CYP2c9-inh | 0.704 |
| CYP2c9-sub | 0.788 |
| CYP2d6-inh | 0.336 |
| CYP2d6-sub | 0.38 |
| CYP3a4-inh | 0.169 |
| CYP3a4-sub | 0.266 |
| CL | 12.862 |
| T12 | 0.476 |
| hERG | 0.01 |
| Ames | 0.033 |
| ROA | 0.679 |
| SkinSen | 0.829 |
| Carcinogencity | 0.809 |
| EI | 0.521 |
| Respiratory | 0.469 |
| NR-Aromatase | 0.764 |
| Antiviral | Yes |
| Prediction | 0.72102 |